Trust Signals
Key Takeaways
Direct Answer: Tesamorelin Peptide vs Sermorelin in Plain Terms
Tesamorelin is the more potent, better-studied, and structurally superior GHRH analog, with human RCT evidence for visceral fat reduction and an active FDA approval. Sermorelin is cheaper, widely compounded, and has a longer safety record in clinical use but lacks modern RCT data in its primary off-label application. For most off-label wellness uses, neither has strong evidence over the other.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- How do their structures differ?
- What do they actually do in the body, with real numbers?
- What does the clinical evidence actually show?
- Honest head-to-head comparison table
- What most comparison pages get wrong
- Stability, formulation, and sourcing reality
- Dosing and operational label literacy
- Side effects and contraindications
- Frequently Asked Questions
- Sources
- Disclaimers
How Do Their Structures Differ, and Why Does It Matter?
Endogenous GHRH is a 44-amino-acid peptide. Sermorelin is a synthetic truncation containing only the first 29 amino acids (GHRH 1-29-NH2). That truncation retains GHRH receptor binding but removes residues that contribute to plasma stability. The result is a peptide with a very short plasma half-life measured in minutes in early pharmacokinetic work, though exact values differ across studies and assay conditions.
Tesamorelin contains the full 44-amino-acid sequence and adds a trans-3-hexenoic acid group covalently linked to the tyrosine at position 1 on the N-terminus. This modification reduces dipeptidyl peptidase IV cleavage at the N-terminus, which is the primary degradation pathway for GHRH analogs in plasma. The result is meaningfully longer plasma exposure per dose. The prescribing information for Egrifta SV reports a mean half-life of approximately 26 minutes for tesamorelin versus much shorter durations for unmodified GHRH fragments, though direct controlled comparisons with sermorelin using the same assay are not published in the open literature.
What Do They Actually Do in the Body, with Real Numbers?
Both peptides bind the pituitary GHRH receptor (GHRHR), a G-protein-coupled receptor, triggering cyclic AMP accumulation, protein kinase A activation, and downstream release of stored growth hormone from somatotroph cells. This is a stimulatory mechanism, not a replacement mechanism. The pituitary retains its somatostatin-mediated braking system, which is why physiologic pulsatility is better preserved than with exogenous GH.
GH then acts on the liver to increase insulin-like growth factor-1 (IGF-1) synthesis, which mediates most downstream body composition effects. In the Falutz 2010 NEJM trial of tesamorelin at 2 mg/day subcutaneously, IGF-1 standard deviation scores rose from baseline values in the GH-deficient range to near-normal values at 26 weeks, with mean IGF-1 increases of roughly 60 to 100 mcg/L depending on the study subgroup. Visceral adipose tissue decreased by approximately 15 to 18% by CT measurement. These numbers are specific to the HIV lipodystrophy population and cannot be automatically extrapolated to healthy aging adults.
Sermorelin at typical compounded doses (0.2 to 0.3 mg daily in adults) stimulates a GH pulse within 30 to 45 minutes of injection. Published IGF-1 data for sermorelin in adults are mostly from pediatric GH deficiency trials and small adult studies; none provide the robust CT-measured body composition endpoints that the tesamorelin trials do.
What Does the Clinical Evidence Actually Show?
Evidence Ledger
| Claim | Best Evidence Type | Peptide | Effect Direction | Confidence |
|---|---|---|---|---|
| Reduces visceral fat in HIV lipodystrophy | Phase 3 RCT (Falutz et al., NEJM 2010, n=412) | Tesamorelin | Positive, ~15-18% VAT reduction | High |
| Raises IGF-1 in HIV lipodystrophy | Phase 3 RCT | Tesamorelin | Positive | High |
| Improves GH secretion in pediatric GHD | Multiple controlled trials, historical | Sermorelin | Positive | Moderate |
| Reduces visceral fat in healthy aging adults | No RCT for either peptide in this population | Both | Uncertain | Very Low |
| Improves lean mass in healthy aging adults | Small studies, mechanistic inference | Both | Possible, small | Low |
| Improves sleep quality | Mechanistic inference, anecdotal | Both | Unproven | Very Low |
| Cognitive benefit in MCI (tesamorelin) | Small RCT, Baker et al., Neurology 2021 | Tesamorelin | Positive signal on memory measures | Low (single small trial) |
| Long-term safety beyond 12 months | Extension trial (Spooner et al., 2012) | Tesamorelin | Generally maintained, glucose caution | Moderate |
Honest Head-to-Head Comparison
| Factor | Tesamorelin | Sermorelin | Winner (or "Neither") |
|---|---|---|---|
| FDA approval status | Approved (Egrifta SV, HIV lipodystrophy) | Withdrawn 2008 (commercial, not safety) | Tesamorelin |
| Amino acid length | 44 AA + N-terminal modification | 29 AA, no modification | Tesamorelin (pharmacokinetics) |
| Plasma half-life | Approximately 26 min (Egrifta PI) | Minutes; shorter than tesamorelin | Tesamorelin |
| Human RCT evidence | Yes, in HIV lipodystrophy (n=412) | Yes, in pediatric GHD; limited in adults | Tesamorelin for adult body composition |
| Evidence in healthy aging adults | Very limited | Very limited | Neither |
| Typical compounded cost | Higher | Lower | Sermorelin |
| Branded product availability | Yes (Egrifta SV) | No branded product currently | Tesamorelin |
| Dosing frequency | Once daily (approved protocol) | Once daily (typical compounded protocol) | Equal |
| Preserves pituitary feedback | Yes | Yes | Equal |
| Compounding availability in US | Available from 503B pharmacies | Available from 503A/503B pharmacies | Sermorelin (broader access) |
| Glucose tolerance risk | Documented in RCTs | Probable but less characterized | Tesamorelin better characterized (more data) |
What Most Comparison Pages Get Wrong
Most content on tesamorelin vs sermorelin treats both peptides as equally validated anti-aging tools and then differentiates them only by potency. That framing has three serious errors.
Error 1: Ignoring indication specificity. Tesamorelin's RCT evidence is almost entirely in HIV-positive adults with lipodystrophy, a population with a specific metabolic phenotype. Applying the 15 to 18% visceral fat reduction figure to a healthy 45-year-old man is an extrapolation with no direct support. The physiology is different.
Error 2: Treating compounded sermorelin as equivalent to studied sermorelin. Compounded sermorelin products vary widely in purity, excipients, and reconstitution vehicle. Batch-to-batch consistency is not equivalent to an FDA-approved product. The peptide in a vial from a 503A pharmacy may have the correct sequence but lacks the pharmacokinetic and bioavailability validation that supported any published study.
Error 3: Omitting the bioavailability ceiling for subcutaneous GHRH analogs. Subcutaneous bioavailability of peptides in this size range is real but incomplete and variable depending on injection site, adipose tissue depth, and inter-individual differences in peptidase activity in the subcutaneous compartment. Relative bioavailability figures for tesamorelin from subcutaneous vs intravenous delivery exist in the prescribing information and are well below 100%, meaning dose math from IV pharmacokinetic models does not translate directly to SQ dosing.
Stability, Formulation, and Sourcing Reality
Why peptides degrade and what accelerates it. Both tesamorelin and sermorelin are polypeptides held together by amide (peptide) bonds. In aqueous solution, those bonds hydrolyze, a rate that increases with temperature and certain pH ranges. Lyophilization (freeze-drying) dramatically slows this by removing the water needed for hydrolysis. This is why both products are supplied as lyophilized powders and must be reconstituted only immediately before use or in small batches stored refrigerated.
Egrifta SV's labeling specifies refrigerated storage before reconstitution and limited post-reconstitution stability. Compounded sermorelin vials carrying bacteriostatic water as the diluent extend in-use shelf life compared to sterile water because bacteriostatic water contains benzyl alcohol as a preservative. However, benzyl alcohol itself can cause peptide conformational changes over extended storage periods. Neither diluent makes a reconstituted peptide indefinitely stable.
Sourcing red flags for compounded peptides. The 2024 FDA guidance on compounded peptides created significant market disruption. Products labeled as "research use only" or sold without a prescription and without a COA showing: HPLC purity above 98%, mass spectrometry confirmation of molecular weight, endotoxin (LAL assay) results below USP injectable limits, and sterility testing should be considered unverified for human use. A batch failing endotoxin testing but having correct sequence would still carry injection fever risk.
Dosing, Reconstitution, and Label Literacy
| Parameter | Tesamorelin (Egrifta SV) | Sermorelin (Compounded) |
|---|---|---|
| Approved/typical dose | 2 mg SQ once daily | 0.2 to 0.3 mg SQ once daily (off-label) |
| Injection site | Abdomen (approved labeling) | Abdomen, rotate sites |
| Reconstitution volume | Per Egrifta SV instructions (2.2 mL) | Varies by vial concentration; check COA |
| Timing | Once daily | Often dosed at bedtime to align with nocturnal GH pulse |
| Storage after reconstitution | Refrigerate, use within labeled window | Refrigerate, typically use within 30 days |
| What degraded product looks like | Particulates, cloudiness, off-color | Same: cloudiness, particulates, unusual odor |
Reconstitution math check. If a compounded sermorelin vial contains 6 mg of lyophilized peptide and you add 2 mL bacteriostatic water, concentration is 3 mg/mL. A 0.25 mg dose requires 0.083 mL, drawn in an insulin syringe as approximately 8 units on a 100-unit/1 mL syringe. Always verify your concentration before drawing. A 10-fold dosing error is possible if you assume a different concentration than what is labeled.
Side Effects and Who Should Not Use Either Peptide
Both tesamorelin and sermorelin carry risks that are mechanistically linked to elevating GH and IGF-1. The Falutz 2010 tesamorelin trial documented fluid retention, arthralgias, and glucose intolerance as the most common adverse events. A meaningful minority of tesamorelin-treated patients developed elevated glucose or worsened diabetes (exact proportions are in the Egrifta prescribing information and varied by subgroup). Sermorelin carries the same mechanistic risks but with less precise published frequency data in adults.
Absolute contraindications for both: active malignancy (GH and IGF-1 are mitogenic), pregnancy (no safety data), known pituitary tumor or cranial irradiation history, and hypersensitivity to the peptide or excipients. Caution is warranted in pre-diabetic or diabetic patients, patients with active carpal tunnel syndrome, and those with significant fluid retention conditions.
Antibody formation against tesamorelin has been documented in clinical trials. Egrifta prescribing information notes that a proportion of patients develop anti-tesamorelin antibodies, and a smaller proportion develop antibodies cross-reactive with endogenous GHRH, though this did not clearly correlate with loss of efficacy in trial populations. This phenomenon has not been as well characterized for compounded sermorelin.
Frequently Asked Questions
What is the core structural difference between tesamorelin and sermorelin?
Sermorelin is a 29-amino-acid truncated analog of endogenous GHRH (GHRH 1-29). Tesamorelin is the full 44-amino-acid GHRH sequence with a trans-3-hexenoic acid group conjugated to the N-terminus, which significantly extends its plasma half-life by reducing dipeptidyl peptidase IV cleavage.
Is tesamorelin FDA-approved?
Yes. Tesamorelin (brand name Egrifta) received FDA approval in 2010 specifically for reducing excess abdominal fat (lipodystrophy) in HIV-positive adults on antiretroviral therapy. Sermorelin previously had FDA approval for pediatric growth hormone deficiency but that approval was withdrawn by the manufacturer in 2008 for commercial reasons, not safety.
Which peptide produces a larger increase in IGF-1?
Head-to-head human RCT data do not exist. Tesamorelin at 2 mg/day produced IGF-1 increases of roughly 60 to 100 mcg/L in HIV lipodystrophy trials. Sermorelin data come largely from smaller studies in growth hormone deficiency; direct IGF-1 comparison to tesamorelin in healthy adults is not established by high-quality evidence.
What is the approved dose of tesamorelin?
The FDA-approved dose for tesamorelin (Egrifta SV) is 2 mg injected subcutaneously once daily into the abdomen. Off-label compounded protocols vary, and those doses lack the regulatory validation of the approved product.
Does sermorelin work after the pituitary is no longer functional?
No. Both tesamorelin and sermorelin are GHRH receptor agonists and require an intact, responsive pituitary gland to stimulate growth hormone release. Neither works in patients with pituitary failure or destruction. This is a key mechanistic distinction from synthetic growth hormone.
How stable are these peptides after reconstitution?
Both are lyophilized peptides that degrade meaningfully once reconstituted. Manufacturer guidance for Egrifta SV specifies refrigeration after reconstitution and use within a defined window. Compounded sermorelin vials should be kept refrigerated and used promptly; peptide bonds hydrolyze faster in solution at higher temperatures.
Can either peptide be taken orally?
No. Both are polypeptides that are rapidly degraded by gastrointestinal proteases. Subcutaneous injection is the only validated route for both peptides. Oral or sublingual preparations have no credible pharmacokinetic data supporting systemic bioavailability.
What side effects are shared by both peptides?
Both can cause injection site reactions, fluid retention, arthralgia, and elevated IGF-1 effects such as insulin resistance. Tesamorelin clinical trials documented glucose intolerance in a meaningful minority of participants. Both are contraindicated in active malignancy, pregnancy, and pituitary tumor history.
Is tesamorelin worth the higher cost over sermorelin?
For the specific FDA-approved indication of HIV-associated lipodystrophy, tesamorelin has robust RCT evidence and sermorelin does not. For off-label anti-aging or body composition use in non-HIV adults, neither has high-quality RCT evidence, making the cost premium for tesamorelin harder to justify on evidence grounds alone.
Do these peptides suppress the body's own GHRH production?
Unlike exogenous growth hormone, GHRH receptor agonists preserve the normal pulsatile feedback loop. They stimulate the pituitary rather than replace output, so suppression of endogenous GHRH is not a primary concern. However, chronic IGF-1 elevation can modulate somatostatin tone over time.
What should a COA for a compounded sermorelin or tesamorelin product show?
A legitimate COA should include HPLC purity (ideally above 98%), mass spectrometry confirming molecular weight, endotoxin testing (LAL assay), sterility testing, and peptide sequence confirmation. Absence of endotoxin and sterility data is a red flag for any compounded injectable peptide.
Sources
- Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin, a growth hormone-releasing factor analog, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. Journal of Acquired Immune Deficiency Syndromes. 2010;53(3):311-322.
- Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine. 2007;357(23):2359-2370.
- Egrifta SV (tesamorelin for injection) Prescribing Information. Theratechnologies Inc. Current version available via FDA Drugs@FDA database.
- Baker LD, Barsness SM, Borson S, et al. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults. Archives of Neurology. 2012;69(11):1420-1429.
- Baker LD, et al. Cognitive changes associated with tesamorelin in mild cognitive impairment. Neurology. 2021 (see PubMed for current indexed version).
- Spooner LM, Olin JL. Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy. Annals of Pharmacotherapy. 2012;46(2):240-247.
- FDA. Sermorelin acetate (Geref): product discontinuation. FDA Drug Shortages and Discontinuations. 2008.
- FDA. Guidance for Industry: Compounding of Certain Peptide Drug Products Under Sections 503A and 503B of the FD&C Act. 2024.
- Alba M, Fintini D, Salvatori R. Effects of N-terminal modifications of growth hormone-releasing hormone on plasma half-life and receptor binding. Journal of Endocrinology. 2005 (see PubMed for specific indexed citation).
- United States Pharmacopeia. General Chapter 1 on Injections and Implanted Drug Products: endotoxin and sterility requirements. USP-NF current edition.
Footer Disclaimers
Platform. FormBlends is an informational platform. This page does not constitute medical advice, a diagnosis, or a treatment recommendation. Consult a licensed healthcare provider before initiating any peptide therapy.
Research Compound and Compounded Medication Notice. Sermorelin is available as a compounded medication from licensed 503A and 503B pharmacies in the United States. Compounded products are not FDA-approved and have not undergone the same review for safety, efficacy, or manufacturing quality as approved drugs. Tesamorelin is available as the FDA-approved product Egrifta SV; compounded versions exist but carry the same caveats as other compounded peptides. All off-label use of these compounds is the responsibility of the prescribing clinician.
Results. Individual results vary. The clinical outcomes described on this page derive from specific trial populations (primarily HIV-positive adults with lipodystrophy) and may not apply to healthy aging adults, athletes, or other populations. Effect sizes observed in controlled trials are not guarantees of individual outcomes.
Trademark. Egrifta and Egrifta SV are registered trademarks of Theratechnologies Inc. FormBlends has no affiliation with Theratechnologies. All trademarks are the property of their respective owners.